Reduced inflammatory response in cigarette smoke exposed Mrp1/Mdr1a/1b deficient mice

Margaretha van der Deen1, Wim Timens2, Hetty Timmer-Bosscha1, Barry W van der Strate2, Rik J Scheper3, Dirkje S Postma4, Elisabeth G de Vries1 and Huib A Kerstjens*4

Address: 1Medical Oncology Department, University Medical Center Groningen and University of Groningen, The Netherlands, 2Pathology Department, University Medical Center Groningen and University of Groningen, The Netherlands, 3Pathology Department, VU University Medical Center, Amsterdam, The Netherlands and 4Pulmonology Department, University Medical Center Groningen and University of Groningen, The Netherlands

Email: Margaretha van der Deen - margaretha.vanderdeen@umassmed.edu; Wim Timens - w.timens@path.umcg.nl; Hetty Timmer-Bosscha - h.timmer-bosscha@int.umcg.nl; Barry W van der Strate - B.W.A.van.der.Strate@med.umcg.nl; Rik J Scheper - R.J.Scheper@vumc.nl; Dirkje S Postma - d.s.postma@int.umcg.nl; Elisabeth G de Vries - e.g.e.de.vries@int.umcg.nl; Huib A Kerstjens* - h.a.m.kerstjens@int.umcg.nl

* Corresponding author

Abstract

Background: Tobacco smoke is the principal risk factor for chronic obstructive pulmonary disease (COPD), though the mechanisms of its toxicity are still unclear. The ABC transporters multidrug resistance-associated protein 1 (MRP1) and P-glycoprotein (P-gp/MDR1) extrude a wide variety of toxic substances across cellular membranes and are highly expressed in bronchial epithelium. Their impaired function may contribute to COPD development by diminished detoxification of noxious compounds in cigarette smoke.

Methods: We examined whether triple knock-out (TKO) mice lacking the genes for Mrp1 and Mdr1a/1b are more susceptible to develop COPD features than their wild-type (WT) littermates. TKO and WT mice (six per group) were exposed to 2 cigarettes twice daily by nose-only exposure or room air for 6 months. Inflammatory infiltrates were analyzed in lung sections, cytokines and chemokines in whole lung homogenates, emphysema by mean linear intercept. Multiple linear regression analysis with an interaction term was used to establish the statistical significances of differences.

Results: TKO mice had lower levels of interleukin (IL)-7, KC (mouse IL-8), IL-12p70, IL-17, TNF-alpha, G-CSF, GM-CSF and MIP-1-alpha than WT mice independent of smoke exposure (P < 0.05). IL-1-alpha, IL-6, IL-8, IL-13, IL-17, TNF-alpha, G-CSF, GM-CSF and MCP-1 increased after smoke exposure in both groups, but the increase in IL-8 was lower in TKO than WT mice (P < 0.05) with a same trend for G-CSF (P < 0.10). Smoke-induced increase in pulmonary inflammatory cells in WT mice was almost absent in TKO mice. The mean linear intercept was not different between groups.

Conclusion: Mrp1/Mdr1a/1b knock-out mice have a reduced inflammatory response to cigarette smoke. In addition, the expression levels of several cytokines and chemokines were also lower in lungs of Mrp1/Mdr1a/1b knock-out mice independent of smoke exposure. Further studies are required to determine whether dysfunction of MRPI and/or P-gp contribute to the pathogenesis of COPD.
Background
Tobacco smoke generates oxidative stress in the lungs and is the principal risk factor for the development of chronic obstructive pulmonary disease (COPD). Main features of COPD are airway inflammation and destruction of alveolar tissue. Little is known about detoxification and elimination processes of noxious substances present in cigarette smoke. Proteins of the ATP-binding cassette (ABC) superfamily such as multidrug resistance-associated protein 1 (MRP1) and P-glycoprotein (P-gp, encoded by the MDR1 gene) protect against oxidative stress, chemotherapy drugs and xenobiotics [1,2] by transporting a wide variety of toxic substances across cellular membranes. MRP1 and P-gp are highly expressed in human and mouse lung and are mainly located at the basolateral and apical side of bronchial epithelium respectively [3,4]. So far, the function of these ABC transporters in the lung is unknown [5]. They possibly detoxify carcinogenic compounds and other noxious gasses and particles present in tobacco smoke [6]. Thus a defective function may play a role in the pathogenesis of lung cancer and COPD.

Mrp1 (-/-) and Mdr1a/-/b (-/-) mice (in contrast to humans, rodents have two genes for P-gp, called Mdr1a and Mdr1b), are healthy and fertile under normal conditions [7,8]. Mice that lack Mrp1 and both Mdr1a/-/b genes, from here on called triple knock-out (TKO) mice, seem physiologically normal as well [9]. However, all these knock-out mice are highly sensitive to several chemotherapeutic drugs. In addition,Mrp1 (-/-) mice display elevated glutathione levels in tissues that normally have a high MRP1 expression, e.g. in the lungs [7], possibly as a compensation mechanism for the elevated pulmonary oxidative stress. Furthermore, these mice have an impaired inflammatory response [10] that is probably due to lower leukotriene C4 (LTC4, a proinflammatory mediator) excretion by macrophages or granulocytes since LTC4 is a physiologic substrate for MRP1 [11].

We detected lower MRP1 expression in bronchial epithelium of COPD patients compared to healthy ex-smokers [12]. In the present study, we investigated whether TKO mice have a different susceptibility to develop cigarette smoke-induced features of COPD compared to their wild-type (WT) littermates.

Methods
Mice
WT male FVB mice were obtained from Harlan (Zeist, the Netherlands). Male FVB Mrp1/Mdr1a/-/b TKO mice were kindly provided by Drs AH Schinkel and P Borst, the Netherlands Cancer Institute, Amsterdam [13]. Mice were held at the central animal facility of the University of Groningen. The animals received standard rodent food (Hope Farms, Woerden, The Netherlands) and water ad libitum.

Experiments were approved by the local committee on animal experimentation, and were performed under strict governmental and international guidelines.

Smoke exposure
Mainstream smoke of research cigarettes (type 2R1, University of Kentucky, KY) was administered by nose-only exposure [14]. The smoke exposure system of the University of Kentucky was used and the system was set up according to instructions of the manufacturer. Six mice per experimental group were exposed to 2 cigarettes per session, 10 puffs per cigarette, twice daily for 5 days per week. Sham control mice were room air-exposed in a separate animal exposure subunit under similar circumstances.

Preparation of lungs
After 6 months smoke or air exposure, the mice were anesthetized with a mixture of isoflurane, N2O, and oxygen, and the trachea was cannulated. Subsequently, the mice were exsanguinated via the abdominal aorta. The right lung was ligated and lung lobes were snap-frozen and stored at -80°C. The left lung was removed, inflated and fixed with formalin with a constant pressure of 25 cm H2O for 24 h. Subsequently, the lung was dissected from the trachea and embedded in paraffin for immunohistochemical evaluation and morphometrical analysis [15].

Morphometrical measurements of emphysema
Three-micron paraffin sections were cut and stained with hematoxylin and eosin (H&E) according to standard methods. Approximately 25 photomicroscopic images per tissue section were prepared at 2.5 × 20 magnifications using a standardized sequence of image capturing. Images with large vessels, conducting airways or pleura occupying 25% or more of the total image were not used for the mean linear intercept (Lmi) analysis which was assessed as a measure of alveolar airspace enlargement by two independent individuals in a blinded manner [15,16]. Mean values per mouse were used for statistical analysis.

Cytokine and chemokine analysis in lung homogenates
One part of frozen lung tissue (17 to 30 mg) of each mouse was homogenized in buffer (50 mM Tris-HCl, 150 mM NaCl, 0.002% Tween-20, pH = 7.5) in 10% w/v for 1 to 2 min and subsequently centrifuged for 10 min, 12,000 g at 4°C. Supernatants were stored at -80°C until analysis. Cytokines and chemokines that might play a role in cellular defense mechanisms against cigarette smoke or smoke-induced cellular damage were measured by means of a multiplex Luminex ELISA system (Lincoplex Systems, St Charles, MO). These included: interleukin (IL)-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, keratinocyte chemoattractant (KC, murine homologue of IL-8), IL-9, IL-10, IL-12p70, IL-13, IL-15, IL-17, tumor necrosis factor-alpha (TNFα),
interferon-gamma (IFNγ), granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage-colony stimulating factor (GM-CSF), IFN-inducible protein-10 (IP-10), MCP-1 (monocyte chemoattractant protein-1), macrophage inflammatory protein 1-alpha (MIP1α) and regulated upon activation, normal T-cell expressed and secreted (RANTES). The concentrations of cytokines and chemokines were expressed as pg/g total lung tissue.

**Immunohistochemical analysis of infiltrates in lung tissue**
The presence of inflammatory cells in paraffin embedded lung sections (3 μm) was evaluated with a semi-quantitative score. The total number of infiltrates in three different sections of each lung were counted. The infiltrates were mainly clustered together in groups, not as single cells. Clusters of 25 cells or more were considered positive. Of every mouse lung, the infiltrates in three sections were averaged and the average per experimental group (4–6 mice) was calculated. All sections were cut in a similar way, i.e. in the same plane and 250 micrometer from the start of sectioning of the tissue. In this way, the counting area was similar in all sections.

Specific monoclonal antibodies anti-Neutrophil (Cedarlane, Sanbio, Uden, The Netherlands), MAC-3 and B220 (both from BD Pharmingen, San Jose, CA) were used to detect the presence of neutrophils, macrophages, and B-cells respectively. Detection of these antibodies was performed using biotin-labeled rabbit-anti-rat antibodies (SouthernBiotech, ITK, Uithoorn, The Netherlands) as the second step and alkaline phosphatase-labeled streptavidin (Dako, Glostrup, Denmark) as the third step. New fuchsin (Dako, Glostrup, Denmark) was used as a chromogen and methyl green for nuclear counterstaining.

Frozen sections were stored at -20°C until use. After thawing, slides were incubated in acetone for 10 min. Subsequently, sections were incubated with specific antibodies for CD3, CD4 and CD8-positive T-cells (antibodies from BD Pharmingen). Detection of CD4 and CD8 antibodies was performed using biotin-labeled goat-anti-rat antibodies as the second step. Anti mouse-CD3 polyclonal serum (from hamster) was detected by polyclonal biotin-labeled mouse-anti-hamster antibodies (BD Pharmingen) and the third step was streptavidin-peroxidase complex (Dako, Glostrup, Denmark). Amino-ethyl carbazole (AEC) (Sigma Aldrich, Zwijndrecht, The Netherlands) was used as chromogen, and hematoxylin was used for nuclear counterstaining. All incubation steps were carried out at room temperature. PBS/1% BSA or irrelevant isotype specific antibodies were used as negative controls. Mouse spleen was used as positive control.

**Statistical analysis**
All data are expressed as the mean ± SD. Multiple linear regression analysis with an interaction term was used to establish the statistical significances of differences in terms of genotype (TKO or WT) and cigarette smoke exposure for each parameter. This method disentangles the separate effects of cigarette smoke and genotype and their interaction. A significant interaction indicates that the effect of the combination is significantly different (larger or smaller) than the addition of the separate effects of smoke exposure and the genotype. When the interaction term was significant, the regression coefficients of the separate effects of smoking and of genotype were taken from this model. In cases of no significant interaction, the interaction term was removed from the analysis and the coefficients were taken from the model with only smoking and genotype. The normal distribution was tested with a Kolmogorov-Smirnov test and data were logarithmically transformed when needed to normalize distributions. A value of $P < 0.05$ was considered significant. Statistical analyses were performed with SPSS 10 (SPSS Inc, Chicago, IL).

**Results**
Two sham control mice of the WT group died of unknown cause in the last month before ending the experiment. Autopsy did not reveal specific pathology, in particular no indications of infection. Malignancies were not observed in lungs of either WT or TKO mice.

**Cytokines and chemokines**
Levels of IL-7, IL-8, IL-12p70, IL-17, TNFα, G-CSF, GM-CSF and MIP1α in whole lung homogenates were significantly lower in TKO mice than WT mice independent of smoke exposure (Table 1). After 6 months smoke exposure, IL-1α, IL-6, IL-8, IL-13, IL-17, TNFα, G-CSF, GM-CSF and MCP-1 in lungs of mice were elevated in TKO and WT mice (Table 1). The results of IL-8, G-CSF, TNFα, and MIP1α measurements are depicted in Figure 1A–D. The increase of IL-8 in response to smoke was less in TKO mice compared to WT mice ($P = 0.047$), with a similar trend for G-CSF production ($P = 0.096$) (Figure 1 and Table 1, smoke × genotype interaction term).

**Evaluation of inflammatory cells and emphysema**
There were significantly lower numbers of lymphoid inflammatory cells in the paraffin lung sections of smoke-exposed TKO mice as compared to WT mice ($P = 0.02$) (Figure 2). Lymphoid infiltrates as well as pigmented (smoke particles positive) macrophages could be distinguished. Representative pictures are shown in Figure 3. Almost no infiltrates were detected in the lungs of TKO and WT mice that were not exposed to smoke. The lymphoid infiltrates consisted mainly of B-cells surrounded by CD4 positive and CD8 positive cells and their relative
distribution was comparable between WT and TKO smoke-exposed mice. Neutrophils were present in very low numbers in all experimental groups and were not further analyzed.

Mean Lmi values ranged from 18.3 to 23.5 µm (Figure 4). There was a slight increase of airspace size after 6 months smoke exposure in both TKO and WT mice. However, no significant differences in Lmi values were measured between the four groups. The body weight of the mice was not significantly different between the groups before and after smoke exposure.

**Discussion**

Our data show that the inflammatory response to cigarette smoke exposure in lungs of *Mrp1/Mdr1a/1b* TKO mice is reduced as compared to WT mice. This is illustrated by lower numbers of inflammatory cells in lung sections as well as by lower levels of IL-8 and G-CSF in total lung extracts. This is the first study that reports lower smoke-induced pulmonary inflammation in relation to absence of ABC transporters. In addition, the expression levels of several cytokines and chemokines were also lower in lungs of TKO mice independent of smoke exposure.

A possible explanation of the lower inflammatory response in TKO mice is an impaired transport of the pro-inflammatory mediator LTC4, an important physiological high-affinity substrate for MRP1 [10]. In a study with inoculation of *Streptococcus pneumoniae*, *Mrp1*(-/-) mice displayed a better survival compared to WT mice. This was accompanied by a lower LTC4 concentration but a higher LTB4 level in bronchoalveolar lavage fluid [17]. In contrast, the outgrowth of *Mycobacterium tuberculosis* was enhanced in *Mrp1*(-/-) mice [18]. Other interesting observations are that it has been shown that MRP1 regulates the migration of dendritic cells by transporting LTC4, which acts as a chemoattractant for dendritic cells to lymph nodes [19]. The differentiation of dendritic cells is also dependent on MRP1 function [20]. Furthermore, in *Mdr1a*(-/-) mice, migration of dendritic cells to draining lymph nodes is impaired [21]. The above-mentioned observations on dendritic cells may contribute to the decreased inflammatory response following smoke exposure that we measured in lungs of TKO mice.

IL-8 levels were markedly decreased upon smoke exposure in lungs of TKO mice. IL-8 is induced by smoking and elevated in lungs of COPD patients [22]. It is mainly excreted by neutrophils, alveolar macrophages and epithelial cells

---

**Table 1: Cytokines and chemokines in lung homogenates.**

| Cytokines/Chemokines | Values in pg/g lung homogenate (mean (SD)) | P-values | Smoke × Genotype interaction | Smoke effect | Genotype effect |
|----------------------|---------------------------------------------|----------|-------------------------------|-------------|----------------|
| **IL-1α**            | 118.4 (38.1) 195.3 (42.8) 120.8 (22.0) 158.6 (40.8) | NS       | 0.00 ↑ | NS                      |
| **IL-1β**            | 54.0 (10.6) 61.5 (12.8) 50.4 (6.6) 51.7 (6.6) | NS       | NS             | NS         | NS                      |
| **IL-2**             | 87.9 (35.9) 80.3 (20.3) 70.8 (13.3) 80.3 (23.5) | NS       | NS             | NS         | NS                      |
| **IL-4**             | 4.5 (0.8) 5.0 (0.6) 4.1 (0.6) 4.7 (0.7) | NS       | NS             | NS         | NS                      |
| **IL-5**             | 23.6 (3.8) 24.4 (7.1) 22.7 (3.6) 23.9 (6.6) | NS       | NS             | NS         | NS                      |
| **IL-6**             | 45.4 (11.6) 117.5 (58.0) 47.5 (6.0) 76.0 (17.7) | NS       | 0.01 ↑ | NS                      |
| **IL-7**             | 192.1 (26.4) 196.2 (28.0) 162.0 (9.8) 183.2 (24.4) | NS       | NS             | 0.05 ↓                 |
| **IL-8 (KC)**        | 147.1 (58.2) 755.2 (448.0) 133.1 (41.1) 291.8 (93.7) | 0.05 ↓   | 0.01 ↑ | 0.01 ↓                 |
| **IL-9**             | 136.3 (38.4) 123.6 (21.0) 111.3 (25.1) 107.9 (14.5) | NS       | NS             | NS         | NS                      |
| **IL-10**            | 359.6 (124.4) 359.4 (103.9) 384.4 (186.4) 366.9 (48.4) | NS       | NS             | NS         | NS                      |
| **IL-12p70**         | 213.9 (30.7) 213.6 (30.6) 173.9 (15.5) 198.9 (21.0) | NS       | NS             | 0.03 ↓                 |
| **IL-13**            | 40.3 (5.3) 49.8 (13.8) 36.8 (2.7) 45.9 (7.5) | NS       | 0.02 ↑ | NS                      |
| **IL-15**            | 99.0 (21.7) 108.0 (15.8) 84.9 (7.4) 98.2 (11.9) | NS       | NS             | NS         | NS                      |
| **IL-17**            | 20.4 (2.5) 34.2 (16.3) 17.6 (1.4) 20.8 (1.8) | NS       | 0.05 ↑ | 0.04 ↓                 |
| **TNFα**             | 14.2 (2.4) 17.7 (2.9) 11.8 (1.9) 13.8 (1.4) | NS       | 0.01 ↑ | 0.00 ↓                 |
| **IFNγ**             | 80.5 (24.4) 73.1 (14.6) 80.0 (25.4) 78.3 (12.6) | NS       | NS             | NS         | NS                      |
| **G-CSF**            | 124.9 (3.2) 121.3 (24.8) 215.7 (4.7) 275.2 (21.1) | NS       | 0.10 ↓ | 0.02 ↑ | 0.03 ↓                 |
| **GM-CSF**           | 36.2 (5.7) 40.5 (5.4) 30.1 (1.4) 35.4 (5.7) | NS       | 0.03 ↑ | 0.01 ↓                 |
| **IP-10**            | 297.8 (116.5) 431.9 (304.5) 232.9 (108.4) 220.7 (74.1) | NS       | NS             | NS         | NS                      |
| **MCP-1**            | 38.0 (2.4) 46.9 (7.2) 29.1 (2.0) 48.2 (24.2) | NS       | 0.02 ↑ | NS                      |
| **MIP1α**            | 600.1 (46.4) 657.3 (83.7) 491.3 (42.9) 516.0 (82.1) | NS       | NS             | 0.00 ↓                 |
| **RANTES**           | 37.4 (8.7) 50.3 (38.0) 57.1 (43.9) 33.9 (11.4) | NS       | NS             | NS         | NS                      |

WT wild-type; TKO triple knock-out mice; Sm smokers; NSm non-smokers; SD standard deviation; NS not significant. See text for further details.
and a chemoattractant for neutrophils. This is consistent with the decrease in number of macrophages that we observed in lung tissue of TKO mice after smoke exposure. Neutrophils were present in low numbers in both WT and TKO mice, thus, differences in neutrophil recruitment by IL-8 to the lungs could not be detected. Intriguingly, IL-8 is known to be involved in tissue repair reactions [23] and both the IL-8 and G-CSF response tended to be lower in TKO mice. G-CSF has been reported to promote lung regeneration as well, supposedly by mobilization of bone marrow derived cells to alveolar tissue [24]. However, the precise role of IL-8 and G-CSF in COPD development and/or prevention remains to be investigated. The decreased excretion of these two cytokines might result in a delayed lung regeneration mechanism. This question cannot be answered in this study, as 6 months smoking was not sufficient to induce emphysema in these WT and TKO mice (see discussion below).

The main question is whether the reduced inflammatory response in TKO mice could be related to the development of COPD. In a longitudinal study, we recently reported that COPD patients who stopped smoking had an increase in inflammatory cells in induced sputum and we hypothesized that this might actually be beneficial by augmenting the defense capacity [25]. Therefore, the decrease in inflammatory response in TKO mice in our current study could be detrimental instead of beneficial, but we currently have no further data to support this hypothesis.

We have previously detected lower MRP1 expression in bronchial epithelium of COPD patients compared to healthy matched controls who were all ex-smokers [12]. These results support our original hypothesis that lower expression is associated with COPD development and hence we anticipated more detrimental effects of cigarette smoke in Mrp1 knock-out or Mrp1/Mdr1a/1b TKO mice. Further support for this hypothesis comes from studies with NRF2 (nuclear factor-E2 p45-related factor). NRF2, a transcription factor for many genes that play a role in anti-
oxidant defense and detoxification processes, was recently also identified as a transcription factor for MRP1 [26]. Interestingly, the onset of cigarette smoke-induced emphysema was earlier and the extent of emphysema was more severe in Nrf2 (-/-) mice than in wild-type mice [27]. The number of inflammatory cells (mainly macrophages) in bronchoalveolar lavage fluid and lung tissue was higher in Nrf2 (-/-) mice. The absence of only the two proteins Mrp1 and P-gp in our knock-out model compared to the absence of the transcription factor NRF2 that regulates many genes involved in oxidative defense, may explain differences in outcome of this study and ours.

The smoke induced pulmonary infiltrates consisted of B-cells surrounded by T-cells and macrophages. Hogg et al. observed such follicles in the small airways of humans with COPD [28] and we described these B-cell follicles in our smoking mouse model of emphysema and in lung parenchyma of patients with COPD [15]. We hypothesized that these B-cells secrete antibodies directed against extracellular matrix proteins or tobacco smoke components but the source of the antigen(s) remains to be elucidated. D’hulst and colleagues have recently shown smoke-induced emphysema in SCID mice [29]. They suggested that functional B- and T-cells are not required to induce emphysema but, as they also point out, this does not exclude the possibility that the lymphoid follicles could contribute to loss of alveolar tissue and the decline in lung function in COPD patients.

We did not observe emphysema in both WT and TKO mice after 6 months of smoke exposure. With the same smoke exposure protocol, we have successfully induced emphysema in C57BL/6J mice [15]. Possibly, FVB mice are more resistant to smoke-induced emphysema than C57BL/6J mice, as differences in vulnerability are known to occur between mouse strains [30,31]. To measure differences in alveolar destruction or lung cancer, smoke exposure for a longer period of time or higher smoke doses may be required. We used the Lmi method for evaluation of emphysema development that measures airspace enlargement only. Lmi is an artificial measurement.
of frequency of presence of structures like alveolar walls. Several other methods can be used to measure features of emphysema including “destructive index” and “internal surface area”. These methods capture other aspects of emphysema but have high correlations with Lmi. However, they are considerably more time consuming. Since the results on Lmi were so clearly negative, we chose not to invest in an additional method that most probably would not provide different information; we are unaware of studies with significant differences in one method, that did not even give a trend in another method of emphysema measurement.

We questioned whether the lack of Mrp1/Mdr1a/1b would be compensated for by induction of expression of other MDR proteins of the ATP-binding cassette family i.e. Mrp2, 3, 4, 5, 6, 9 and breast cancer resistance protein (Bcrp). The immunohistochemical expression of these transporters was low or absent, except for Mrp3 which was expressed at the apical side of bronchial epithelium of FVB mice, however, this may be due to an aberrant staining of this antibody (M3II-2) as other antibodies for Mrp3 were negative in human and mice lung tissue [4]. We observed no differences in expression of all these transporters in Mrp1/Mdr1a/1b triple knockout mice compared to wild-type mice, nor did we observe effects of smoking on expression of Mrp1 and P-gp in WT mice or on all other analyzed transporter proteins in lungs of both WT and TKO mice (data not shown). These results indicate that indeed Mrp1 and P-gp are the most important transporters present in the lung and that cigarette smoke exposure did not up- or downregulate expression of MDR proteins.

**Conclusion**

The pulmonary inflammatory response to inhalation of cigarette smoke is reduced when Mrp1 and both genes for P-gp are nonfunctional. This includes in particular a poor ability for smoke-induced IL-8 (and G-CSF) production in Mrp1/Mdr1a/1b TKO mice compared to WT mice and altogether, this leads to almost complete absence of inflammatory cells in response to cigarette smoke. An impaired function of MRP1 and/or P-gp may result in insufficient clearance of noxious matter as well. Further research should clarify whether there is a relation between a reduced inflammatory response and impaired tissue repair and thus to an increased risk of developing COPD.

**Competing interests**

The author(s) declare that they have no competing interests.

**Authors’ contributions**

MD drafted the manuscript, processed the lungs, performed Lmi scores and immunohistochemistry and subsequent evaluation, and carried out statistical analysis. WT helped with evolution of histology. HT carried out Lmi scores. BS participated in setting up the model for emphysema induction in mice. WT, RS, DP, EV and HK participated in the design of the study and helped with writing the manuscript. All authors read and approved the final manuscript.

**Acknowledgements**

This work was supported by a grant of the Netherlands Asthma Foundation (NAF97.35), Centocor and Spinoza premium (NWO). The authors thank M Geerlings, M Lodewijk, B Rutgers, M Luinge and P Klok for excellent technical assistance, Dr HM Boezen for critical evaluation of statistical analysis and Anuk Das (Centocor, PA, USA) for performing the Luminex assays. We thank Dr GL Scheffer (VU University Medical Center, Amsterdam) for helpful discussions and providing antibodies against MDR proteins. We are grateful to Drs AH Schinkel and P Borst (the Netherlands Cancer Institute, Amsterdam) for helpful discussions, critical reading of the manuscript and providing us with the Mtp1/Mdr1a/1b knock-out mice.

**References**

1. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992, 258:1650-1654.
2. Balayssac D, Authier N, Cayre A, Coudore F: Does inhibition of P-glycoprotein lead to drug-drug interactions? Toxicol Lett 2005, 156:319-329.
3. Brechot JM, Hurbain I, Fajas A, Daty N, Beruadnia JF: Different pattern of MRP localization in ciliated and basal cells from human bronchial epithelium. J Histochem Cytochem 1998, 46:513-517.
4. Scheffer GL, Pijnenborg AC, Smid EF, Muller M, Postma DS, Timens W, van der Valk P, de Vries EG, Schepers RJ: Multidrug resistance related molecules in human and murine lung. J Clin Pathol 2002, 55:332-339.
5. van der Deen M, de Vries EG, Timens W, Schepers RJ, Timmer-Bosch J, Postma DS: ATP-binding cassette (ABC) transporters in normal and pathological lung. Respir Res 2005, 6:59.
6. Leslie EM, Ito K, Upadhyaya P, Hecht SS, Deeley RG, Cole SP: Transport of the beta-O-glucuronide conjugate of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by the multidrug resistance protein 1 (MRP1). Requirement for glutathione or a non-sulfur-containing analog. J Biol Chem 2001, 276:27846-27854.
7. Lorico A, Rappa G, Finch RA, Yang D, Flavell RA, Sartorelli AC: Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione. Cancer Res 1997, 57:5238-5242.
8. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, van der Valk MA, Vooroud CJ, Spits H, van Tellingen O, Zijlman JM, Fibbe WE, Borst P: Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporing) P-glycoproteins. Proc Natl Acad Sci USA 1997, 94:4028-4033.
9. Johnson DR, Finch RA, Lin ZP, Zeiss CJ, Sartorelli AC: The pharmacological phenotype of combined multidrug-resistance mdr1a/1b- and mdr1-deficient mice. Cancer Res 2001, 61:1469-1476.
10. Wijnholds J, Evers R, van Leusden MR, Mol CA, Zaman GJ, Mayer U, Beijnen JH, van der Valk M, Krupenfort P, Borst P: Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nat Med 1997, 3:1275-1279.
11. Lieber J, Jedlitschky G, Buchholz U, Keppeler D: Characterization of the ATP-dependent leukotriene C4 export carrier in mastocyteoma cells. Eur J Biochem 1994, 220:599-606.
12. van der Deen M, Marks H, Willemsen BW, Postma DS, Muller M, Smid EF, Scheffer GL, Schepers RJ, de Vries EG, Timens W: Diminished expression of multidrug resistance-associated protein 1 (MRP1) in bronchial epithelium of COPD patients. Virchows Arch 2006, 449:682-688.
13. Vlahos R, de Lange EC, Scheffer GL, van den Berg DJ, Mol CA, van der Valk M, Schinkel AH, Scheper RJ, Breimer DD, Borst P. Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J Clin Invest 2000, 105:279-285.

14. Griffith RB, Hancock R. Simultaneous mainstream-sidestream smoke exposure systems I. Equipment and procedures. Toxicology 1985, 34:123-138.

15. van der Strate BW, Postma DS, Brandsma CA, Melgert BN, Luinge MA, Geerlings M, Hylkema MN, van den Berg A, Timens W, Kerstjens HA: Cigarette Smoke-induced Emphysema: A Role for the B Cell? Am J Respir Crit Care Med 2006, 173:751-758.

16. Thurlbeck WM: Measurement of pulmonary emphysema. Am Rev Respir Dis 1967, 95:752-764.

17. Schultz MJ, Vlahos J, Peppelenbosch MP, Vervoordeldonk MJ, Speelman P, van Deventer SJ, Borst P, van der Poll T: Mice lacking the multidrug resistance protein 1 are resistant to Streptococcus pneumoniae-induced pneumonia. J Immunol 2001, 166:4059-4064.

18. Verbon A, Leemans JC, Weijer S, Florquin S, van der Poll T: Mice lacking the multidrug resistance protein 1 have a transiently impaired immune response during tuberculosis. Clin Exp Immunol 2002, 130:12-36.

19. Robbiano DF, Finch RA, Jager D, Muller WA, Sartorelli AC, Randolph GJ: The leukotriene C(4) transporter MRP1 regulates CCL19 (MIP-3beta, ELC)-dependent mobilization of dendritic cells to lymph nodes. Cell 2000, 103:757-768.

20. van de Ven R, de Jong MC, Reurs AW, Schoonderwoerd AJ, Jansen G, Hooijberg JH, Scheffer GL, de Grijff TD, Schepere RJ: Dendritic cells require multidrug resistance protein 1 (ABCC1) transporter activity for differentiation. J Immunol 2006, 176:5191-5198.

21. Xu D, Regnér M, Smith D, Ruby J, Johnstone R, Mullbacher A: The multidrug resistance gene mdr1a influences resistance to ectromelia virus infection by mechanisms other than conventional immunity. Immuno Cell Biol 2004, 82:462-470.

22. Pease JE, Sabroe I: The role of interleukin-8 and its receptors in inflammatory lung disease: implications for therapy. Am J Respir Med 2002, 1:19-23.

23. de Boer WI: Cytokines and therapy in COPD: a promising combination? Chest 2002, 121:2095-2185.

24. Ishizawa K, Kubo H, Yamada M, Kobayashi S, Numasaki M, Ueda S, Suzuki T, Sasaki H: Bone marrow-derived cells contribute to lung regeneration after elastase-induced pulmonary emphysema. FEBS Lett 2004, 556:249-252.

25. Willemsen BW, ten Hacken NH, Rutgers B, Lesman-Leegte IG, Postma DS, Timens W: Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers. Eur Respir J 2005, 26:835-845.

26. Hayashi A, Suzuki H, Itoh K, Yamamoto M, Sugiyama Y: Transcription factor Nrf2 is required for the constitutive and inducible expression of multidrug resistance-associated protein 1 in mouse embryonic fibroblasts. Biochem Biophys Res Commun 2003, 310:824-829.

27. Rangasamy T, Cho CY, Thimmulappa RK, Zhen L, Srivasa S, Kersler TW, Yamamoto M, Petroch I, Tudor RM, Biswal S: Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. J Clin Invest 2004, 114:1248-1259.

28. Hogg JC, Chu F, Uotakoparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciruba FC, Coxson HO, Pare PD: The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004, 350:2645-2653.

29. Dhulst AI, Maes T, Breuke KR, Demets IK, Tournay KG, Joos GF, Brusselle GG: Cigarette smoke-induced pulmonary emphysema in scid-mice. Is the acquired immune system required? Respir Res 2005, 6:1-47.

30. Guerassimov A, Hoshino Y, Takubo Y, Turcotte A, Yamamoto M, Chezzo H, Triantafillopoulos A, Whitaker K, Hoidal JR, Cosio MG: The development of emphysema in cigarette smoke-exposed mice is strain dependent. Am J Respir Crit Care Med 2004, 170:974-980.

31. Vitali R, Boszinovski S, Jones BE, Powell J, Gras J, Lilja A, Hansen MJ, Guinaldo RC, Irving L, Anderson GP: Differential protease, innate immunity, and NF-kappaB induction profiles during lung inflammation induced by subchronic cigarette smoke exposure in mice. Am J Physiol Lung Cell Mol Physiol 2006, 290:L931-L945.